Another study illustrated that combining pan-RAF (RAF265) and mTOR inhibitors (RAD001) enhanced the anti-tumor effects through the RAS-RAF and PI3K pathways, possibly through targeting the 4EBP1 and S6 protein [286]. Here, RAF1 is linked to neoplasm.